Prohost Biotech
HomeArticlesImpacting NewsEli Lilly Neutralizing Antibody LY-CoV555 Promises a Reduction in the Rate of COVID-19 Hospitalizations  
Impacting News
Premium

Eli Lilly Neutralizing Antibody LY-CoV555 Promises a Reduction in the Rate of COVID-19 Hospitalizations  

Eli Lilly and AbCellera Collaboration Result LY-C0V555  A lot of discoveries, followed by thorough experimentation beyond the vaccines, are taking place in the biotechnology and large biopharmaceutica...
P

Prohost Biotech

1 min read
33
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Tags

AbCellera
Eli Lilly (LLY)
SARS-CoV-2 (the virus that causes COVID-19)

Comments (0)

Please sign in to join the discussion

Related Articles

Impacting News
Premium

Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Total 1Q 2026 net product revenue of   $191.2 million, representing 57% year-over-year growth   AUVELITY ®   1Q 2026 net product sales of   $153.2 million, representing 59% year-over-year growth   SUN...
P

Prohost Biotech

May 6, 2026

1m
377
Impacting News
Premium

Neurocrine Biosciences Acquires Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio

Neurocrine ...
P

Prohost Biotech

Apr 8, 2026

1m
290
Impacting News
Premium

FDA Approved Lilly's Foundayo™ (orforglipron), the Only GLP-1 Pill for Weight Loss That Can Be Taken Any Time of Day Without Food or Water Restrictions

Eli Lilly in the NEWS INDIANAPOLIS, April 1, 2026 /PRNewswire/, Eli Lilly and Company ( LLY ) , announced the U.S. FDA approved Foundayo™ (orforglipron) for adults with obesity, or overweight with wei...
P

Prohost Biotech

Apr 2, 2026

1m
327